Aptar Pharma touts FDA approval of nasal spray device

Aptar Pharma said this week that its Bidose nasal spray device won FDA approval for use with a breakthrough depression therapy.

The Crystal Lake, Ill.-based company’s Bidose tech enables two-shot nasal drug delivery. Aptar touted its manufacturing facility in Congers, NY, which supports the manufacture of nasal and injectable drug delivery systems.

“We are pleased that Aptar Pharma’s Bidose nasal delivery device has been approved by the FDA for this breakthrough therapy in the field of depression,” Aptar Pharma president Gael Touya said in prepared remarks. “This project marks close to a 10-year customer collaboration and once again demonstrates Aptar Pharma’s ability to develop and launch complex drug delivery systems worldwide.”

Last May, Aptar announced another partnership with digital therapeutics company Propeller Health to develop a portfolio of connected drug delivery devices.

In 2016, the pair of companies launched the world’s first fully-integrated connected metered dose inhaler. Now, they’ve set their sights on a platform of digital therapeutics.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.